Honestly, man. If this plays out and people realise the data for...

Honestly, man.

If this plays out and people realise the data for Bisantrene and efficacy in AML alone was worth $2.5B MC, they are going to feel like right twats.

ATH could be smashed literally any day from here to the end of the year. The majority of what RAC do is done secretly, but something that is quite clear to me and should be to everyone else:

If RAC want to drive a large scale buyout within the next 4-years, the only way to do that is show Bisantrene is a platform play. This means collecting as much human data as possible from multiple P2 trials in as many synergies as possible. The precursors to that work (which has been very clearly stated in public announcements) is being completed now and can come at any time.